|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ITU logo | INTERNATIONAL TELECOMMUNICATION UNION  **TELECOMMUNICATION STANDARDIZATION SECTOR**  STUDY PERIOD 2017-2020 | | | **TD 241** | |
| **TSAG** | |
| **Original: English** | |
| **Question(s):** | | | N/A | Geneva, 26 February – 2 March 2018 | |
| **TD** | | | | | |
| **Source:** | | | TSB | | |
| **Title:** | | | Statistics on ITU-T Recommendations and patent declarations | | |
| **Purpose:** | | | Information | | |
| **Contact:** | | Anibal Cabrera TSB | | | Tel: +41 22 730 6371 |

|  |  |
| --- | --- |
| **Keywords:** | Intellectual property; IPR; licensing; patent statements. |
| **Abstract:** | This TD presents the statistics on patents requested by the 2017 meeting of TSAG (Item 13.3 of the TSAG report) |

**Action**: TSAG is invited to consider this document.

The ITU IPR database, which is accessible from the ITU-T IPR webpage <http://itu.int/ipr>, presents an intuitive and flexible interface that allows users to search for IPR information tailored to their needs.

Further to the information accessible via this interface, the June 2017 meeting of TSAG requested TSB to gather the following additional statistics:

1. The total number of Recommendations approved per year and the number of Recommendations protected by IPR rights per year
2. The total number of Recommendations approved per study group, with indication of the number of declared IPR statements
3. The total number of Recommendations approved per Recommendation series, with indication of the number of declared IPR statements
4. If available, information regarding the time of adoption of the Recommendation and the first claimed IPR.

Below we provide the number of Recommendations and associated patent declarations for items 1), 2) and 3) for the last five years. However, the information for item 4) cannot be gathered as patent declarations are registered against a specific product that comprises all editions of the base text, their amendments and corrigenda, and each has its own approval date. As such, it is not possible to estimate the delay between a patent declaration and the product.

The graphics also provide statistics on the number of patent statements and licensing declaration forms (PSLDFs) received. It should be noted that as patent owners have no obligation to list their patents in their PSLDF, some PSLDFs provide details on specific patents while others do not.

1. **Recommendations, amendments and corrigenda approved versus number of patent declarations from 2013 to 2017**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  | | --- | --- | --- | --- | | **Year** | **Approved Recs/Amds** | **Recs/Amds with patents** | **PSLDFs received** | | 2013 | 220 | 71 | 45 | | 2014 | 271 | 75 | 61 | | 2015 | 320 | 75 | 70 | | 2016 | 469 | 100 | 106 | | 2017 | 275 | 61 | 84 | | **Total** | **1555** | **382** | **366** | |
|  |

1. **Recommendations, amendments and corrigenda approved per study group between 2013 and 2017, with indication of the corresponding number of declared patent statements**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  | | --- | --- | --- | --- | | **SG** | **Approved Recs/Amds** | **Recs/Amds with patents** | **PSLDFs received** | | TSAG | 12 | 0 | 0 | | SG2 | 27 | 0 | 0 | | SG3 | 10 | 0 | 0 | | SG5 | 164 | 5 | 3 | | SG9 | 44 | 11 | 32 | | SG11 | 111 | 5 | 6 | | SG12 | 112 | 37 | 26 | | SG13 | 98 | 12 | 13 | | SG15 | 364 | 207 | 164 | | SG16 | 353 | 86 | 108 | | SG17 | 200 | 11 | 8 | | SG20 | 60 | 8 | 6 | | **Total** | **1555** | **382** | **366** | |
|  |

1. **The total number of Recommendations approved per Recommendation series between 2013 and 2017, with indication of the corresponding number of declared patent statements**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  | | --- | --- | --- | --- | | **Series** | **Approved Recs/Amds** | **Recs/Amds with patents** | **PSLDFs received** | | A | 12 | 0 | 0 | | D | 10 | 0 | 0 | | E | 14 | 1 | 2 | | F | 20 | 2 | 6 | | G | 375 | 218 | 173 | | H | 305 | 62 | 95 | | J | 52 | 19 | 32 | | K | 95 | 5 | 3 | | L | 91 | 0 | 0 | | M | 16 | 0 | 0 | | P | 72 | 24 | 21 | | Q | 113 | 2 | 2 | | T | 18 | 14 | 0 | | X | 140 | 14 | 12 | | Y | 156 | 21 | 20 | | Z | 66 | 0 | 0 | | **Total** | **1555** | **382** | **366** | |
|  |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_